or Try an Advanced Search...

    Technical Analysis for EQ - Equillium, Inc.

    Grade Last Price % Change Price Change
    F 0.72 2.59% 0.02
    EQ closed up 2.59 percent on Wednesday, November 20, 2024, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EQ trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 2.59%
    NR7 Range Contraction 2.59%
    Narrow Range Bar Range Contraction 2.59%
    Inside Day Range Contraction 2.59%
    Wide Bands Range Expansion 2.59%
    Older End-of-Day Signals for EQ ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    Rose Above Previous Day's High about 20 hours ago
    Up 3% about 20 hours ago
    Up 2% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    EQ Chart by TradingView
    Basic chart:

    Profile

    Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders

    Is EQ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Equillium GAAP EPS of $0.00 misses by $0.02, revenue of $12.16M beats by $0.61M
    Nov 13 Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
    Nov 13 Equillium to Present at the Stifel Healthcare Conference
    Nov 12 Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
    Nov 6 Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
    Oct 31 Equillium says Ono not acquiring itolizumab, stock craters 36%
    Oct 31 Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
    Oct 31 Equillium Maintains Rights to Itolizumab Following Ono Partnership
    Oct 31 Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
    Oct 22 Alto Ingredients And 2 Other US Penny Stocks To Watch Closely
    See more EQ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.4789
    Average Volume 182,065
    200-Day Moving Average 1.31
    50-Day Moving Average 0.90
    20-Day Moving Average 0.89
    10-Day Moving Average 0.74
    Average True Range 0.10
    RSI (14) 40.48
    ADX 22.08
    +DI 20.87
    -DI 25.89
    Chandelier Exit (Long, 3 ATRs) 1.20
    Chandelier Exit (Short, 3 ATRs) 0.97
    Upper Bollinger Bands 1.38
    Lower Bollinger Band 0.40
    Percent B (%b) 0.32
    BandWidth 109.87
    MACD Line -0.08
    MACD Signal Line -0.06
    MACD Histogram -0.0193
    Fundamentals Value
    Market Cap 25.22 Million
    Num Shares 35.1 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -3.26
    Price-to-Sales 1.27
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.77
    Resistance 3 (R3) 0.76 0.74 0.76
    Resistance 2 (R2) 0.74 0.73 0.74 0.76
    Resistance 1 (R1) 0.73 0.72 0.74 0.73 0.75
    Pivot Point 0.71 0.71 0.71 0.71 0.71
    Support 1 (S1) 0.70 0.70 0.70 0.70 0.68
    Support 2 (S2) 0.68 0.69 0.68 0.68
    Support 3 (S3) 0.67 0.68 0.68
    Support 4 (S4) 0.67